The impact on CD146 congestion biomarker by early adding SGLT2i dapaglifozin to intravenous loop diuretic in patients with acute heart failure

17 May 2025 (08:00 - 12:45)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Ioan Radu Lala

Victor Babes Hospital, Timisoara (Romania)

4 More presentations in this session

Presentation thumbnail

Optimisation of renin-angiotensin-aldosterone system inhibitors use in chronic kidney disease patients with heart failure: is hyperkalaemia a barrier?

Professor E. Kelepouris (Philadelphia, US)

Abstract Slides Video

Presentation thumbnail

Factors influencing the up-titration to 10 mg target dose of vericiguat: data from a large observational cohort-study in the US.

Doctor A. Michel (Basel, CH)

Abstract Slides Video

Presentation thumbnail

Addition of sodium-glucose cotransporter-2 inhibitors on steroidal mineralocorticoid receptor antagonists eliminates hyperkalemia risk in diabetic heart failure patients with chronic kidney disease

Assistant Professor A. Sahin (Canakkale, TR)

Abstract Slides Video

Presentation thumbnail

Introduction and optimization of the guideline-directed medical therapy in patients hospitalized for acute heart failure (OPTICARD)

Doctor G. Baudry (Nancy, FR)

Abstract Slides Video

Access the full session

Session thumbnail

Congestion, SGLT2 inhibitors and novel therapies

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025

You may be interested in

Congress Presentation

Dapaglifozin in advanced heart failure patients : effects on congestion, NTproBNP and cardiorenal outcome

Congress Presentation

Acute diuretic effect of empagliflozin in de novo heart failure: a secondary analysis of the EMPAG-HF trial

Congress Presentation

Could combined diuretic therapy increase decongestion in patients with acute heart failure?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources